Factor IX: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
(4 intermediate revisions by the same user not shown) | |||
Line 9: | Line 9: | ||
The first cleavage is at Arg145, generating an inactive FIXα. The second cleavage is at Arg180 results in a catalytically active molecule FIXaβ. This resulting heterodimer is held by a disulfide bridge at Cys132-Cys289. The serine protease contains a catalytic triad of <scene name='Factor_IX/Ixstructure_catalytictriad/3'>His221, Asp269, and Ser365</scene><ref>PMID:9374470</ref>. Upon cleave at Arg180, Val181 can form a salt bridge with Asp364, which is a characteristic of active serine proteases. The active FIXa, can then interact with its cofactor, FVIIIa, to form a membrane-bound Xase complex, which activated FX to FXa. | The first cleavage is at Arg145, generating an inactive FIXα. The second cleavage is at Arg180 results in a catalytically active molecule FIXaβ. This resulting heterodimer is held by a disulfide bridge at Cys132-Cys289. The serine protease contains a catalytic triad of <scene name='Factor_IX/Ixstructure_catalytictriad/3'>His221, Asp269, and Ser365</scene><ref>PMID:9374470</ref>. Upon cleave at Arg180, Val181 can form a salt bridge with Asp364, which is a characteristic of active serine proteases. The active FIXa, can then interact with its cofactor, FVIIIa, to form a membrane-bound Xase complex, which activated FX to FXa. | ||
For activated factor IX see [[Factor IXa]]. | |||
See [[Colored & Bioluminescent Protein]].<br /> | See [[Colored & Bioluminescent Protein]].<br /> | ||
[[Mg-8 may contribute to the binding to factors VIIa and X]]<br /> | |||
[[Conformation-specific anti-Factor IX antibodies]]. | [[Conformation-specific anti-Factor IX antibodies]]. | ||
Line 154: | Line 157: | ||
</StructureSection> | </StructureSection> | ||
==Additional Resources== | ==Additional Resources== |